Jupiter Topco LLC Takes Position in LeMaitre Vascular, Inc. $LMAT

Jupiter Topco LLC bought a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 8,132 shares of the medical instruments supplier’s stock, valued at approximately $781,000.

Several other large investors have also recently bought and sold shares of LMAT. Legal & General Group Plc acquired a new position in LeMaitre Vascular in the second quarter valued at approximately $4,840,000. The Manufacturers Life Insurance Company acquired a new stake in shares of LeMaitre Vascular in the 2nd quarter valued at about $1,047,000. Van Hulzen Asset Management LLC purchased a new position in LeMaitre Vascular during the 2nd quarter worth approximately $959,000. Ranger Investment Management L.P. acquired a new position in LeMaitre Vascular during the second quarter worth approximately $21,045,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new stake in LeMaitre Vascular in the second quarter valued at approximately $102,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Wall Street Analysts Forecast Growth

LMAT has been the topic of several research reports. Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, August 14th. Wells Fargo & Company dropped their price target on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 5th. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Finally, Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $110.60.

LeMaitre Vascular Stock Performance

Shares of LMAT stock opened at $80.67 on Monday. The stock has a fifty day moving average price of $91.88 and a 200 day moving average price of $99.18. The stock has a market cap of $1.84 billion, a PE ratio of 28.31, a P/E/G ratio of 2.33 and a beta of 0.50. LeMaitre Vascular, Inc. has a 1 year low of $78.27 and a 1 year high of $118.01. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.81 by ($0.07). The business had revenue of $70.38 million for the quarter, compared to analysts’ expectations of $71.47 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business’s revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.60 earnings per share. Sell-side analysts forecast that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th were paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend was Thursday, August 20th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 35.09%.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.